- Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosisC Collin
Department of Neurorehabilitation, Royal Berkshire and Battle NHS Trust, Reading, UK
Eur J Neurol 14:290-6. 2007..014). Eight withdrawals were attributed to adverse events (AEs); six were on active preparation and two on placebo. We conclude that this CBM may represent a useful new agent for treatment of the symptomatic relief of spasticity in MS...
- Multivariate analysis of the Fugl-Meyer outcome measures assessing the effectiveness of GENTLE/S robot-mediated stroke therapyFarshid Amirabdollahian
Think Lab, The University of Salford, Maxwell Building, Salford, M5 4WT, UK
J Neuroeng Rehabil 4:4. 2007..In this paper we present the results obtained from trialling the GENTLE/S neurorehabilitation system assessed using the upper limb section of the Fugl-Meyer (FM) outcome measure...
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosisC Collin
Royal Berkshire and Battle Hospitals NHS Trust, London Road, Reading, Berkshire RG1 5AN, UK
Neurol Res 32:451-9. 2010..Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients...